| 臺大學術典藏 |
2022-03-22T08:25:46Z |
Continuum simulation of non-local effects in a granular silo discharge flow using a regularized μ (I) rheology model
|
Lin C.-C;Yang F.-L.; Lin C.-C; Yang F.-L.; FU-LING YANG |
| 臺大學術典藏 |
2022-03-22T08:25:08Z |
Development of an interdisciplinary prediction system combining sediment transport simulation and ensemble method
|
Ho H.-C;Chiang Y.-M;Lin C.-C;Lee H.-Y;Huang C.-C.; Ho H.-C; Chiang Y.-M; Lin C.-C; Lee H.-Y; Huang C.-C.; HONG-YUAN LEE |
| 臺大學術典藏 |
2022-03-22T08:25:07Z |
Development of an interdisciplinary prediction system combining sediment transport simulation and ensemble method
|
Ho H.-C;Chiang Y.-M;Lin C.-C;Lee H.-Y;Huang C.-C.; Ho H.-C; Chiang Y.-M; Lin C.-C; Lee H.-Y; Huang C.-C.; HAO-CHE HO |
| 臺大學術典藏 |
2022-03-15T05:39:31Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
WEI-WU CHEN; Lin C.-C.; Huang T.-C.; Cheng A.-L.; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2022-03-15T05:39:21Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; WEI-WU CHEN; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-03-15T03:29:02Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Lin C.-C.; TA-CHEN HUANG; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2022-03-15T03:29:02Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
TA-CHEN HUANG; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-03-14T12:48:18Z |
Topoisomerase II inhibition suppresses the proliferation of telomerase-negative cancers
|
Hsieh M.-H.; Tsai C.-H.; Lin C.-C.; TSAI-KUN LI; Hung T.-W.; Chang L.-T.; Hsin L.-W.; Teng S.-C. |
| 臺大學術典藏 |
2022-03-14T12:48:16Z |
Regioselective synthesis and biological evaluation of: N -substituted 2-aminoquinazolin-4-ones
|
Liao Z.-Y.; Yeh W.-H.; Liao P.-Y.; Liu Y.-T.; Chen Y.-C.; Chen Y.-H.; Hsieh T.-H.; Lin C.-C.; Lu M.-H.; Chen Y.-S.; Hsu M.-C.; TSAI-KUN LI; Chien T.-C. |
| 臺大學術典藏 |
2022-03-10T05:59:20Z |
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy
|
Shih S.-R.; Liao S.-L.; Shih C.-W.; Wei Y.-H.; Lu T.-X.; Chou C.-H.; Yen E.-Y.; YI-CHENG CHANG; Lin C.-C.; Chi Y.-C.; Yang W.-S.; Tsai F.-C. |
| 臺大學術典藏 |
2022-03-10T02:31:40Z |
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3
|
PO-HAN LIN; Lin C.-C.; Yang H.-I.; Li L.-Y.; Bai L.-Y.; Chiu C.-F.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-Y.; Ho C.-M.; Yang S.-F.; Peng C.-T.; Tsai F.-J.; Yeh S.-P. |
| 臺大學術典藏 |
2022-03-10T02:31:39Z |
Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma
|
Lin C.-C.; Chen T.-T.; Lin C.-Y.; Hsieh C.-Y.; PO-HAN LIN; Chien C.-R.; Chiu C.-F.; Yeh S.-P. |
| 臺大學術典藏 |
2022-03-10T02:31:38Z |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation
|
Yeh S.-P.; Lo W.-C.; Hsieh C.-Y.; Bai L.-Y.; Lin C.-C.; PO-HAN LIN; Lin C.-Y.; Liao Y.-M.; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-10T02:31:38Z |
Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer
|
Lien M.-Y.; Liu L.-C.; Wang H.-C.; Yeh M.-H.; Chen C.-J.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Li L.-Y.; PO-HAN LIN; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-10T02:31:36Z |
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
|
PO-HAN LIN; Li H.-Y.; Fan S.-C.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T.; Ni Y.-H.; Chiu C.-F. |
| 臺大學術典藏 |
2022-03-08T08:27:21Z |
The fungal metabolite, citrinin, inhibits lipopolysaccharide/interferon- γ-induced nitric oxide production in glomerular mesangial cells
|
Liu, Biing-Hui; Chi J.-Y.; Hsiao Y.-W.; Tsai K.-D.; Lee Y.-J.; Lin C.-C.; Hsu S.-C.; Yang S.-M.; Lin T.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:07Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
SHIH-HUNG YANG; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2022-03-08T03:44:03Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-04T08:22:50Z |
Annular esophageal leiomyoma mimicking a foregut cyst on endoscopic ultrasound
|
Lin C.-C.; JYH-CHIN YANG; Wang H.-P.; Lee J.-M.; Liu K.-L. |
| 臺大學術典藏 |
2022-03-04T08:22:48Z |
Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker
|
Tseng C.-W.; JYH-CHIN YANG; Chen C.-N.; Huang H.-C.; Chuang K.-N.; Lin C.-C.; Lai H.-S.; Lee P.-H.; Chang K.-J.; Juan H.-F. |
| 臺大學術典藏 |
2022-03-04T05:33:28Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-04T05:33:27Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-01T08:20:14Z |
General anesthesia with propofol (continuous intravenous infusion) supplemented with nitrous oxide: comparison with isoflurane.
|
Huang F.Y.; Huang H.H.; Lun K.C.; Lin Y.S.; MING-JIUH WANG; Lin C.C.; Hou W.Y.; Chen C.L.; Shin L.T.; Chao C.C. |
| 臺大學術典藏 |
2022-02-23T02:19:35Z |
Dimethylarginine Dimethylaminohydrolase 1 Polymorphisms and Venous Intimal Hyperplasia in Hemodialysis Patients
|
CHIH-CHENG WU; Hsieh M.-Y.; Lee C.-K.; Chuang S.-Y.; Chung M.-Y.; Lin C.-C. |
| 臺大學術典藏 |
2022-02-23T02:19:34Z |
Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials
|
Liao M.-T.; Chen M.-K.; Hsieh M.-Y.; Yeh N.-L.; Chien K.-L.; Lin C.-C.; CHIH-CHENG WU; Chie W.-C. |
| 臺大學術典藏 |
2022-02-23T02:19:32Z |
Semiparametric mixture cure model analysis with competing risks data: Application to vascular access thrombosis data
|
Chen C.-M.; Shen P.-S.; Lin C.-C.; CHIH-CHENG WU |
| 臺大學術典藏 |
2022-02-23T02:19:31Z |
Correction to: Semiparametric mixture cure model analysis with competing risks data: Application to vascular access thrombosis data (Statistics in Medicine, (2020), 39, 27, (4086-4099), 10.1002/sim.8711)
|
Chen C.-M.; Shen P.-S.; Lin C.-C.; CHIH-CHENG WU |
| 臺大學術典藏 |
2022-02-23T02:19:30Z |
Stent grafts improved patency of ruptured hemodialysis vascular accesses
|
Liao M.-T.; Luo C.-M.; Hsieh M.-C.; Hsieh M.-Y.; Lin C.-C.; Chie W.-C.; Yang T.-F.; CHIH-CHENG WU |
| 臺大學術典藏 |
2022-02-23T02:12:38Z |
Diffuse intraperitoneal metastasis after spontaneous rupture of hepatocellular carcinoma
|
Lin C.-C.; CHIEN-HUNG CHEN; Tsang Y.-M.; Jan I.-S.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-23T02:12:34Z |
Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis
|
Lin C.-C.; Liang H.-P.; Lee H.-S.; Huang G.-T.; Yang P.-M.; Ho M.-C.; Lee P.-H.; Tsang Y.-M.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:17Z |
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
|
Tsai M.-C.; Wang C.-C.; Lee W.-C.; Lin C.-C.; Chang K.-C.; CHIEN-HUNG CHEN; Hung C.-H.; Lin M.-T.; Hsiao C.-C.; Chen C.-L.; Chien R.-N.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:33Z |
Diffuse intraperitoneal metastasis after spontaneous rupture of hepatocellular carcinoma
|
Lin C.-C.; CHIEN-HUNG CHEN; Tsang Y.-M.; Jan I.-S.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:27Z |
Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis
|
Lin C.-C.; Liang H.-P.; Lee H.-S.; Huang G.-T.; Yang P.-M.; Ho M.-C.; Lee P.-H.; Tsang Y.-M.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
|
Tsai M.-C.; Wang C.-C.; Lee W.-C.; Lin C.-C.; Chang K.-C.; CHIEN-HUNG CHEN; Hung C.-H.; Lin M.-T.; Hsiao C.-C.; Chen C.-L.; Chien R.-N.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:39Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
JIH-HSIANG LEE; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; JIH-HSIANG LEE; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:36Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C.; Bai Y.-Y.; JIH-HSIANG LEE; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
